Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda(The University of Texas MD Anderson Cancer Center), Anders Österborg(Karolinska University Hospital), Stephan Stilgenbauer(Universität Ulm), Magdalena Piotrowska(The University of Texas System), Thomas J. Kipps(Moores Cancer Center), Charlotte Russell(The University of Texas System), Joris Wilms(The University of Texas System), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Jiřı́ Mayer(University Hospital Brno), Nedjad Losic(The University of Texas System), Martin J.S. Dyer(The University of Texas System), Tadeusz Robak(Medical University of Lodz), Marek Trněný(The University of Texas System), Tomáš Kozák(The University of Texas System), Geoffrey Chan(The University of Texas System), Cathy Williams(The University of Texas System), Randy Davis(The University of Texas System), Andrzej Hellmann(Gdańsk Medical University), Richard R. Furman(Memorial Sloan Kettering Cancer Center)
Cited by 587
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k